Novan Provides Corporate Update and Reports Third Quarter 2021 Financial Results
November 10, 2021 05:55 ET
|
Novan, Inc.
– Company executing on plans for three potential New Drug Application (NDA) filings in three years with the first submission targeted in Q3 2022 for lead program SB206 in molluscum contagiosum – –...
Novan Appoints Brian M. Johnson as Chief Commercial Officer and Receives Conditional FDA Acceptance of Proposed Brand Name KINSOLUS™ for SB206 in Molluscum Contagiosum
November 02, 2021 08:30 ET
|
Novan, Inc.
– Mr. Johnson brings broad commercial expertise with over 30 years of leadership spanning dermatology marketing, sales, sales management, digital marketing and managed care –– Company received...
Novan Reports Safety Data from B-SIMPLE4 Pivotal Phase 3 Study of SB206
September 23, 2021 08:00 ET
|
Novan, Inc.
– SB206 demonstrates continued favorable safety profile consistent with previous studies and meets Company’s expectations – – Pre-NDA meeting with the FDA, as well as conduct of customary stability...
Novan Announces Strategic Priorities and Outlines Key Milestones
September 09, 2021 07:00 ET
|
Novan, Inc.
– Company planning for three potential New Drug Application (NDA) filings in three years with the first submission expected in Q3 2022 for lead program SB206 in molluscum contagiosum – – Late-stage...
Novan Engages Syneos Health as Commercial Solutions Provider for SB206
September 08, 2021 09:00 ET
|
Novan, Inc.
– Company targeting New Drug Application (NDA) for SB206 in Q3 2022, following recent clinically and statistically significant topline efficacy results from a pivotal Phase 3 B-SIMPLE4 trial in...
Novan Appoints Tomoko Maeda-Chubachi, MD, PhD, MBA as Chief Medical Officer
August 24, 2021 09:00 ET
|
Novan, Inc.
– Dr. Maeda-Chubachi, who served as Novan’s Senior Vice President, Medical has played a key role in the design and execution of the Company’s development programs – – Dr. Maeda-Chubachi was...
Novan Announces Last Patient Visit at Week 24 in B-SIMPLE4 Pivotal Phase 3 Trial of SB206 in Patients with Molluscum Contagiosum
July 28, 2021 08:05 ET
|
Novan, Inc.
– Company previously reported positive topline efficacy and favorable safety data at Week 12 from B-SIMPLE4 in June 2021, with primary endpoint achieving statistical significance with p-value less...
Novan Reports Positive Topline Results from Pivotal Phase 3 Trial of SB206 in Patients with Molluscum Contagiosum
June 11, 2021 06:30 ET
|
Novan, Inc.
– B-SIMPLE4 achieves statistical significance for the primary endpoint with p-value less than 0.0001 – – No serious adverse events related to treatment with SB206 – – Novan intends to submit New...
Novan Announces Final Week-12 Visit for Last Patient in B-SIMPLE4 Pivotal Phase 3 Study of SB206 for Treatment of Molluscum
May 03, 2021 08:30 ET
|
Novan, Inc.
– Topline data on track for readout before the end of Q2 2021 – – Currently no FDA-approved therapies for the treatment of molluscum – – Potential for NDA filing no later than Q3 2022 – DURHAM,...
Novan Completes Enrollment in B-SIMPLE4 Pivotal Phase 3 Study of SB206 for Treatment of Molluscum
February 01, 2021 08:05 ET
|
Novan, Inc.
– Topline data on track for targeted readout before the end of Q2 2021 – – SB206, if approved, has the potential to meet an important need for the treatment of molluscum, an area with no current...